Sorafenib: 10 years after the first pivotal trial.

Sorafenib: 10 years after the first pivotal trial.

Item
http://www.wikidata.org/entity/Q38544841
Targeting Hepatocellular Carcinoma: What did we Discover so Far?Microenvironmental Targets in SarcomaImproving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix.Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling.Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib.The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cellsAMP-activated protein kinase - not just an energy sensor.Protein Synthesis Inhibition and Activation of the c-Jun N-Terminal Kinase Are Potential Contributors to Cisplatin Ototoxicity.Gene expression profiles and pathway enrichment analysis of human osteosarcoma cells exposed to sorafenib.Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review.Evaluating Uncertainty in Signaling Networks Using Logical Modeling
P2860

Sorafenib: 10 years after the first pivotal trial.

Item
http://www.wikidata.org/entity/Q38544841
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Sorafenib: 10 years after the first pivotal trial.
@en
type
label
Sorafenib: 10 years after the first pivotal trial.
@en
prefLabel
Sorafenib: 10 years after the first pivotal trial.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Sorafenib: 10 years after the first pivotal trial
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698